Lynn Stockwell - 26 Sep 2025 Form 4 Insider Report for Drugs Made In America Acquisition II Corp. (DMII)

Reporting relationship: CEO and Exe. Chair of Board, Director, 10%+ Owner
Issuer ticker: DMII
Reported as of: 26 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Oct 2025, 10:40:01 UTC
Prior SEC filing: 24 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Lynn Stockwell

Key filing fact

Lynn Stockwell filed Form 4 for Drugs Made In America Acquisition II Corp. (DMII) on 01 Oct 2025.

Key facts

This page summarizes Lynn Stockwell's Form 4 filing for Drugs Made In America Acquisition II Corp. (DMII).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Oct 2025, 10:40.

Change

Previous filing in this sequence was filed on 24 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001927032 Primary reporting owner

Stockwell Lynn

Relationship: CEO and Exe. Chair of Board, Director, 10%+ Owner
Address: C/O DRUGS MADE IN AMERICA ACQU. II CORP., 1 EAST BROWARD BOULEVARD, SUITE 700, FORT LAUDERDALE
Signature: /s/ Lynn Stockwell
Signature date: 01 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMII transaction

Ordinary shares

Purchase

Transaction value
Shares: +700,000
Change %: +4.9%
Price
Shares after: 15,075,000
Date: 26 Sep 2025
Ownership: See Footnote
Footnotes: F1

DMII transaction

Ordinary shares

Other

Transaction value
Shares: -400,000
Change %: -2.7%
Price
Shares after: 14,675,000
Date: 26 Sep 2025
Ownership: See Footnote
Footnotes: F1, F2

DMII transaction

Ordinary shares

Sale

Transaction value
Shares: -7,966,667
Change %: -54%
Price
Shares after: 6,708,333
Date: 26 Sep 2025
Ownership: See Footnote
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMII transaction Derivative

Rights to receive ordinary shares

Purchase

Transaction value
Shares: +700,000
Change %
Price
Shares after: 700,000
Date: 26 Sep 2025
Ownership: See Footnote
Underlying class: Ordinary shares
Underlying amount: 70,000
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Reflects 700,000 private units acquired by Drugs Made In America Acquisition II LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $7,000,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.

Footnote F2

As of the Transaction Date, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.

Footnote F3

As of the Transaction Date, pursuant to share transfer agreements, the sponsor transferred an aggregate of 7,966,667 ordinary shares to a number of accredited investors for consideration ranging from no consideration to $1.50 per share.

Footnote F4

The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.